期刊文献+

普罗布考在高血压大鼠体内药代动力学的研究

The research on pharmacokinetics of Probucol in Hypertension-rat
下载PDF
导出
摘要 目的研究普罗布考在高血压大鼠体内的药代动力学。方法取10只高血压大鼠灌胃给予普罗布考(10mg/kg),于给药后取体内不同时间(0.5,1.0,1.5,2.0,2.5,3.0,4.0,6.0,9.0h)的血样。用高效液相色谱法测定普罗布考的血药浓度,绘制药-时曲线,采用PKS软件计算药代动力学参数。结果普罗布考在高血压大鼠的药-时曲线符合二室模型,其Tmax为(1.917±2.1)h,Cmax分为(25.61±1.0)μg/ml,t1/2为(2.26±0.01)h。结论采用灌胃普罗布考的大鼠体内药动学呈二室模型,分布较快,代谢较慢。 Objective To study the pharmacokinetics of probucol in hypertension-rat. Methods 10 hypertensive rats were given probucol by ig ,Blood samples were taken at different time(0. 5 ,1.0 ,1.5 ,2.0 , 2. 5 ,3.0 ,4. 0 ,6. 0 ,9. 0 h) ,The plasma concentrations were determined by HPLC and the plasma concentration-time profiles of probucol were obtained. Results The concentration-time curves of probucol were found to fit a two-compartment open model. The Tmax values of probucol was 1. 917 ± 2. 1 h, the Cmax values was 25.61 ± 1.0μg · ml,the t1/2was2. 26 ± 0. 01 h. Conclusion The pharmacokinetics of probucol is fitted for two compartment model with rapid-distribution and metabolic-slower.
出处 《中国现代药物应用》 2010年第4期11-12,共2页 Chinese Journal of Modern Drug Application
关键词 普罗布考 药代动力学 高效液相色谱法 Probucol Pharmacokinetics HPLC
  • 相关文献

参考文献9

  • 1Rinninger F, Wang N, Ramakr ishnan R, et al. Probucol enhances select ire uptake of HDLassociated cholesterol esters in vitro by a scavenger receptor B-I-dependent mechanism. Arterioscler Thromb Vasc Biol, 1999, 19:1325-1332.
  • 2Kuzuya M, Kuzuya F. Probucol as an antioxidant andantiatherogenic drug. Free Radic Biol Med, 1993,14:67-77.
  • 3曹剑,朱冰坡,范利,李小鹰,曾强.普罗布考对老年下肢动脉硬化症的抗氧化和抗炎症作用[J].中国动脉硬化杂志,2006,14(4):336-338. 被引量:14
  • 4严鹏科,廖端芳,杨永宗.普罗布考对巨噬细胞分泌基质金属蛋白酶9的抑制作用[J].中国动脉硬化杂志,2003,11(3):199-202. 被引量:35
  • 5Tadateru Takayama. Aggressive lipid-lowering therapy for secondary prevention in patients with acute coronary syndrome: volumetric and echogenicity analysis using intravascular ultrasound. Tokyo, Japan :68th Scientific Sessions of Japanese CirculationSeciety ,2004: 27-29.
  • 6Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia Fukuoka Atheroscierosis Trial (FAST). J Am Coll Cardiol, 2002:610-616.
  • 7Merat S , Malekzadeh R , Sohrabi MR , et al . Probucol in t he treatment of nonalcoholic steatohepatitis : an open-labeled study. J Clin Gast roenterol ,2003 ,36 (3) :266 -268.
  • 8Merat S , Malekzadeh R , Sohrabi MR , et al . Probucol in t he treatment of nonalcoholic steatohepatitis : Double blind randomized controled study. J Hepatol ,2003 ,38 (4) :414.
  • 9张正,陈宝玲,王珂,黄一玲,方树青,顾德良,方丽,韩少军.普罗布考包合物胶囊在家犬体内的药代动力学与相对生物利用度[J].药学学报,2002,37(3):210-213. 被引量:11

二级参考文献27

  • 1傅琛,夏强,曹春梅,高琴,姚慧,金红峰.活性氧、NO和线粒体ATP敏感钾通道在TNF-α预处理对缺血/再灌注心肌保护中的作用[J].中国应用生理学杂志,2005,21(1):20-24. 被引量:14
  • 2[1]Ambrose JA, Martinez EE. A new paradigm for plaque stabilization. Circulation, 2002, 105 (16): 2 000-004
  • 3[2]Brasen JH, Harsch M, Niendorf A. Survival and cardiovascular pathology of hetero-zygous watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol(0.03%)-enriched diet. Virchows Arch, 1998, 432 (6): 557-562
  • 4[3]Brasen JH, Harsch M, Niendorf A. Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL-rabbits. Virchows Arch, 1995, 426 (2):179-188
  • 5[4]Xu XP, Meisel SR, Ong JM. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human moncyte-derived macrophages. Circulation, 1999, 99: 993-998
  • 6[6]Crisby M, Nordin-Fredriksson G, Shah PK. Pravastatin treatment increases collagen content and decreases lipid content, inflammation,metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation, 2001, 103: 926-933
  • 7[7]Libby P. What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol, 2001, 88: 3J-6J
  • 8[8]Loftus IM, Naylor AR, Goodall S. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke, 2000, 31 (1): 40-47
  • 9[10]Kanaki T, Saito Y. Anti-atherogenic drugs. Nippon Rinsho, 1998, 56 (10): 2 635-639
  • 10Barnhart JW,Sefranka JA,McIntosh DD.Hypocholesterolemic effect of 4,4′-(isopropylidenedithio)-bis(2,6-di-t-butylphenol)(probucol) [J].Am J Clin Nutr,1970,23(9):1229-1233.

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部